For gene therapy of muscular dystrophies, all of the skeletal muscles in the body must be transduced—a tough challenge. An approach that permeabilizes blood vessels using VEGF, helping low doses of a parvovirus-based gene therapy vector sneak across the vessel wall, now solves this problem in mice (pages 828–834).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Gregorevic, P. et al. Nat. Med. 10, 828–834 (2004).
Xia, H., Mao, Q. & Davidson, B.L. Nat. Biotechnol. 19, 640–644 (2001).
Grimm, D. & Kay, M.A. Curr. Gene Ther. 3, 281–304 (2003).
Summerford, C. & Samulski, R.J. J. Virol. 72, 1438–1445 (1998).
Di Pasquale, G. et al. Nat. Med. 9, 1306–1312 (2003).
Halbert, C.L., Allen, J.M. & Miller, A.D. J. Virol. 75, 6615–6624 (2001).
Greelish, J.P. et al. Nat. Med. 5, 439–443 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thomas, C. Gene delivery goes global. Nat Med 10, 782–783 (2004). https://doi.org/10.1038/nm0804-782
Issue Date:
DOI: https://doi.org/10.1038/nm0804-782